Some authors suggested assessment of Androgen receptor in breast cancer in the routine diagnosis, as part of a quadruple panel alongside the assessment of ER, PR, and HER2 to serve as an additional predictive and/or prognostic marker [11, 12]. The gene discussed is PGR; the disease is breast cancer.